Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07626021 Selinexor Polycythemia Vera Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07626021 clinical trial report covering Selinexor, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07625215 BAY-3670549 Atrial Fibrillation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07625215 clinical trial report covering BAY-3670549, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07628062 Nogapendekin alfa inbakicept-pmln HPV16 positive Oropharyngeal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07628062 clinical trial report covering Nogapendekin alfa inbakicept-pmln, Phase 2, endpoints, sponsor, geography, readout timing and development white spa
Latest Hotspot
8 min read
CTR20262236 HL-1186 Herpes Zoster Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
CTR20262236 clinical trial report covering HL-1186, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07628855 Becotatug vedotin Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07628855 clinical trial report covering Becotatug vedotin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07630103 Trastuzumab Rezetecan Metastatic human epidermal growth factor 2 positive carcinoma of breast Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07630103 clinical trial report covering Trastuzumab Rezetecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126260 Chidamide Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
ChiCTR2600126260 clinical trial report covering Chidamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07631000 Cadonilimab Locally Advanced Gastroesophageal Junction Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07631000 clinical trial report covering Cadonilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07630649 Ixoberogene soroparvovec Wet age-related macular degeneration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07630649 clinical trial report covering Ixoberogene soroparvovec, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126264 Temozolomide Glioblastoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
ChiCTR2600126264 clinical trial report covering Temozolomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07630727 AHB-171 Hepatitis B, Chronic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07630727 clinical trial report covering AHB-171, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07631052 Capecitabine ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07631052 clinical trial report covering Capecitabine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.